*Applications will be reviewed on a rolling-basis.
A research opportunity is currently available at the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Translational Sciences/Office of Clinical Pharmacology located in Silver Spring, Maryland.
This project in the Office of Translational Sciences / Office of Clinical Pharmacology / Division of Applied Regulatory Science will explore the utility of -omic technologies to characterize biomarkers of drug response and resistance. This is a high priority project that has the potential to alter in a substantive way the direction of genomic- and transcriptomic-based biomarkers of drug-target interactions and biomarker discovery as well as drug development at the national level.
Under the guidance of a mentor, the participant will be trained in next-generation sequencing technologies, genomics and molecular genetics in cell-based systems, small RNA transcriptomics of clinical samples, and bioinformatic and statistical analyses of data resulting from these experiments. This will inform biomarker discovery of drug response and resistance as well as drug-target interactions and downstream effects in tissues. This training will prepare the participant for a successful career transition into regulatory science research.
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CDER@orau.org. Please include the reference code for this opportunity in your email (FDA-CDER-2021-0716).